Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 287 clinical trials
TEST SITE

This is a 3-arm, randomized, double-blind, double-dummy, and controlled clinical study over 6 months of treatment to evaluate the metabolic and clinical efficacy as well as the safety of DLBS3233 alone, metformin and combination of both, in improving metabolic and reproductive parameters.

  • 0 views
  • 28 Sep, 2022
  • 3 locations
Study Site

This is a 3-arm, randomized, double-blind, double-dummy, and controlled clinical study over 6 months of treatment to evaluate the metabolic and clinical efficacy as well as the safety of DLBS3233 alone, metformin and combination of both, in improving metabolic and reproductive parameters.

  • 0 views
  • 28 Sep, 2022
Test

This is a 3-arm, randomized, double-blind, double-dummy, and controlled clinical study over 6 months of treatment to evaluate the metabolic and clinical efficacy as well as the safety of DLBS3233 alone, metformin and combination of both, in improving metabolic and reproductive parameters.

  • 0 views
  • 26 Sep, 2022
  • 3 locations
Study Test Site  

This is a 3-arm, randomized, double-blind, double-dummy, and controlled clinical study over 6 months of treatment to evaluate the metabolic and clinical efficacy as well as the safety of DLBS3233 alone, metformin and combination of both, in improving metabolic and reproductive parameters.

  • 0 views
  • 28 Sep, 2022
  • 2 locations
Prevention of Skin Problems With Diabetes Devices in Pediatric Patients

A Cluster-controlled Intervention Trial regarding Prevention of Dermatological Complications towards use of Continuous glucose monitoring and insulin pumps in pediatric patients with Type 1 Diabetes. The patients will be followed prospectively with visits every 3rd month for the first year of initiation of device.

diabetes
continuous glucose monitoring
flash
insulin
type 1 diabetes mellitus
  • 0 views
  • 16 Feb, 2024
  • 1 location
Description of Patients With Type 1 Diabetes Treated With Teplizumab (TEPLI-REAL)  

Stage 3 T1D includes presence of islet autoantibodies, overt hyperglycemia, and symptoms; most patients with Stage 3 T1D meet standard diagnostic criteria for diabetes and require insulin treatment.Teplizumab has been shown to delay progression to Stage 3 in participants at Stage 2 in a Phase 2 clinical trial, leading to …

  • 0 views
  • 25 Apr, 2025
Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 Diabetes (KIBOU-T1D)

This is a parallel, Phase 2, two-arm study to assess the efficacy and safety of 14-days intravenous (IV) infusion of teplizumab treatment.Teplizumab has been approved by FDA to delay the onset of Stage 3 Type 1 Diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage …

  • 0 views
  • 25 Jul, 2025
A Study to Look at How Safe NNC0472-0147 is in Healthy People and in People With Type 2 Diabetes

In part 2, participants will either get the new medicine NNC0472-0147 or insulin glargine - which treatment is decided by chance. It is the first time that NNC0472-0147 is tested in humans. Participants will get once daily injections of either NNC0472-0147 or insulin glargine for a treatment period of fourteen …

diabetes
oophorectomy
insulin
cholesterol level
hysterectomy
  • 0 views
  • 16 Feb, 2024
  • 2 locations
Anabolic Effects of Intraoperative Feeding in Reconstruction Surgery

This clinical trial anticipates in determining the beneficial effect of intraoperative feeding to improve intraoperative hemodynamics and enhance postoperative recovery due to attenuation of systemic catabolism and improvement of insulin sensitivity to glycemic control.

cancer
insulin
neck cancer
breakdown
tube feeding
  • 0 views
  • 16 Feb, 2024
  • 1 location
Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults Adolescents and Pediatrics

The purpose of this study is to demonstrate the performance of the Disposable Sensor (DS5) in subjects age 2 - 80 years, for the span of 170 hours (7 days).

type 1 diabetes mellitus
diabetes
continuous glucose monitoring
insulin
type 2 diabetes mellitus
  • 0 views
  • 16 Feb, 2024
  • 13 locations